drugset / Trial / NCT06205134
Comparative Bioavailability of Intranasal Epinephrine
Phase 1/2
Completed
12 enrolled
Nasus Pharma
Hadassah Medical Organization · collabMedistat Ltd., Israel · collabPharma Medica Research, Inc. · collab
RandomizedSequentialOpen-labelTreatment
Summary
A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults
Timeline
- Start
- 2023-08-22
- Primary completion
- 2024-02-02
- Completion
- 2024-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epinephrine | Other / unclassified | 0.3 mg | Intramuscular |
| Subject | Epinephrine | Other / unclassified | 3.6 mg | Intramuscular |
| Subject | Epinephrine | Other / unclassified | 4 mg | Intramuscular |